VeriChip(TM) Announces Results of Italian National Institute Two-Year Clinical Study of VeriMed System

Study Reports Full Patient Acceptance and Flawless Data Retrieval with No Complications 


DELRAY BEACH, Fla., Nov. 30  /PRNewswire-FirstCall/ -- Applied Digital Solutions (NASDAQ:ADSX), though its subsidiary VeriChip Corporation, announced today the results of a clinical study on its VeriMed System for patient radio frequency identification (RFID) conducted by the Spallanzi National Institute of Rome Italy and sponsored by the Italian Ministry of Health.

The two-year, 10 patient study was designed to evaluate the safety and efficacy of the VeriMed implantable RFID microchip and the functionality of the VeriMed System in the management of patients with chronic infectious diseases undergoing care at the Institute. The study reported no complications or side effects related to the insertion procedure, flawless access of the ID number using the hand-held reader, and universal acceptance within the patient study group. Based on the results of the study, the exclusive VeriChip distributor for Italy plans to petition the Italian Ministry of Health for full availability of the VeriMed System through the Italian National Health Service.

Richard Seelig, MD, Vice President, Medical Applications of VeriChip Corporation commented, "We are extremely pleased with the results of the first long-term clinical study evaluating all aspects of the VeriMed System in a clinical management environment. The findings confirm that the VeriMed System provides a favorable clinical utility to treating physicians.   The study also demonstrates the appeal of VeriMed to the patient population as all participants in the study elected to retain their VeriChip implant for use beyond the conclusion of the study."

Mr. Giorgio Fanara, President of Fanara & Associati, who proposed and followed every step and aspect of the Italian study commented: "We would like to express our great satisfaction as now in Italy there is a system capable of meeting and satisfying the universal availability of patient clinical information and guarantee the security of the medical record. I would like to thank Doctor Giorgio Antonucci, Scientific Research Director of the Spallanzi National Institute and all his staff for their high professional skills and great work during these years."

About VeriChip Corporation

VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. VeriChip sells passive RFID systems for identification purposes and active RFID systems for local-area location and identification purposes. VeriChip recently began to market its VeriMed(TM) Patient Identification System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration. For more information on VeriChip, please call 1-800-970-2447, or email . Additional information can be found online at http://www.verichipcorp.com/.

About Applied Digital - "The Power of Identification Technology"

Applied Digital develops innovative identification and security products for consumer, commercial, and government sectors worldwide. The Company's unique and often proprietary products provide identification and security systems for people, animals, the food supply, government/military arena, and commercial assets. Included in this diversified product line are RFID applications, end-to-end food safety systems, GPS/Satellite communications, and telecomm and security infrastructure, positioning Applied Digital as the leader in identification technology. Applied Digital is the owner of a majority position in Digital Angel Corporation (AMEX:DOC).

Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

   Contact:

   Investors:
   Nick Laudico
   The Ruth Group
   646-536-7030
   

   Media:
   Jason Rando
   The Ruth Group
   646-536-7025
   

DATASOURCE: Applied Digital Solutions



CONTACT:  Investors: Nick Laudico,

[phone],

, or Media: Jason Rando, [phone],

, both of The Ruth Group



Web site:  http://www.verichipcorp.com/ 

Copyright